Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
Novo Nordisk has taken another step towards expanding beyond its heartlands of diabetes and obesity with a deal to buy US biotech Corvidia Therapeutics and its lead drug for chronic kidney ...
Novo Nordisk’S OZEMPIC Approval Heat Up The Chronic Kidney Disease Therapeutic Market | Delveinsight
Currently, in Phase III trials for patients with chronic kidney disease, Ziltivekimab became part of Novo Nordisk's portfolio after the company acquired Corvidia Therapeutics in June 2020 for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback